Sandy Draper
Stock Analyst at Guggenheim
(2.91)
# 1,489
Out of 5,131 analysts
113
Total ratings
59.14%
Success rate
20.63%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $595.00 | -27.39% | 12 | Jul 24, 2024 | |
| EVH Evolent Health | Maintains: Hold | $34 → $28 | $4.17 | +571.46% | 10 | May 14, 2024 | |
| IQV IQVIA Holdings | Downgrades: Neutral | n/a | $242.41 | - | 8 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $220.91 | - | 15 | Feb 15, 2024 | |
| GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $2.80 | +257.14% | 4 | Aug 10, 2023 | |
| DOCS Doximity | Downgrades: Neutral | n/a | $43.79 | - | 3 | Aug 9, 2023 | |
| TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $4.18 | -52.15% | 3 | Jun 16, 2023 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $181.38 | +45.00% | 13 | Apr 28, 2023 | |
| AGL agilon health | Maintains: Buy | $21 → $30 | $0.99 | +2,923.89% | 3 | Mar 6, 2023 | |
| HQY HealthEquity | Maintains: Buy | $89 → $94 | $94.15 | -0.16% | 11 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.46 | - | 10 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $23.03 | +121.45% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $234.31 | -44.94% | 2 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $42.04 | +30.83% | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $226 → $168 | $102.11 | +64.53% | 2 | May 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $31.69 | -62.13% | 1 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $8.10 | +517.28% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $13.16 | +393.92% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $2.48 | +1,351.61% | 4 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $240.12 | -30.45% | 3 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.02 | - | 2 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $11.55 | +445.45% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $595.00
Upside: -27.39%
Evolent Health
May 14, 2024
Maintains: Hold
Price Target: $34 → $28
Current: $4.17
Upside: +571.46%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $242.41
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $220.91
Upside: -
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $2.80
Upside: +257.14%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $43.79
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $4.18
Upside: -52.15%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $181.38
Upside: +45.00%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $21 → $30
Current: $0.99
Upside: +2,923.89%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $94.15
Upside: -0.16%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $7.46
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $23.03
Upside: +121.45%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $234.31
Upside: -44.94%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $42.04
Upside: +30.83%
May 12, 2021
Maintains: Buy
Price Target: $226 → $168
Current: $102.11
Upside: +64.53%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $31.69
Upside: -62.13%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $8.10
Upside: +517.28%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $13.16
Upside: +393.92%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $2.48
Upside: +1,351.61%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $240.12
Upside: -30.45%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.02
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $11.55
Upside: +445.45%